Ubs Group Ag Acurx Pharmaceuticals, Inc. Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 38,759 shares of ACXP stock, worth $289,917. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,759
Previous 47
82365.96%
Holding current value
$289,917
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ACXP
# of Institutions
36Shares Held
2.66MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$8.07 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$2.74 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$1.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA146KShares$1.09 Million0.0% of portfolio
-
Morgan Stanley New York, NY106KShares$794,3830.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $86.4M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...